Lymphoma Clinical Trials

Showing 1321-1340 of 3,379 trials

ISTODAX® for Intravenous Infusion Drug Use Results Survey- Relapsed or Refractory Peripheral T-Cell Lymphoma

NCT03742921

To ascertain the safety and efficacy of Istodax® in actual clinical settings in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) who receive Istodax. 1. Planned registration period 4 years 2. Planned surveillance period 5 years and 6 months

Lymphoma, T-Cell, Peripheral

Celgene150 participantsStarted Feb 2019

Osaka, Japan

COMPLETEDPhase 2

Revlimid Dose 25 mg in Association With (R-CHOP) in the Treatment Follicular Lymphoma

NCT01393756

The purpose of the study is to assess the efficacy of the association of Lenalidomide (Revlimid) and R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, vincristine and Prednisone) in a population of patients with follicular lymphoma as measured by the response rate at the end of treatment.

Follicular Lymphoma

The Lymphoma Academic Research Organisation80 participantsStarted Dec 2010

Bordeaux, France • Bordeaux, France • Clermont-Ferrand, France +21 more locations

ISTODAX® for Intravenous Infusion Drug Use Results Survey- Relapsed or Refractory Peripheral T-Cell Lymphoma

Revlimid Dose 25 mg in Association With (R-CHOP) in the Treatment Follicular Lymphoma

Related Searches

Nivolumab Maintenance Therapy After Autologous Stem Cell Transplant in Hodgkin Lymphoma Pts at Relapse/Progression Risk

PET Scan in Planning Treatment in Patients Undergoing Combination Chemotherapy For Stage IA or Stage IIA Hodgkin Lymphoma

Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell Malignancies

Response Adapted Incorporation of Tislelizumab Into the Front-line Treatment of Older Patients With Hodgkin lYmphoma

A Study of TQ-B3525 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Incidence of Severe COVID-19 Infection in Patients With CLL or B-NHL Who Received Pre-exposure Prophylaxis With Tixagevimab and Cilgavimab in Italy.

Ofatumumab-based Induction Chemoimmunotherapy in Previously Untreated Patients With CLL/SLL

Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational)

Phase I/II Study of SyB L-0501RI in Combination With Rituximab to Treat Lymphoma

CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma

Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies

Patient Reported Outcomes and Patient Education in Cellular Therapy Patients

Study of 68GaNOTA-Anti-MMR-VHH2 in Oncological Lesions, Cardiovascular Atherosclerosis, Syndrome With Abnormal Immune Activation and sarcoïdosis

CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study

TreAtments and outComes in paTients With prImary CutAneous Lymphoma

Cardiovascular Events Among Adults Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Standard of Care Chimeric Antigen Receptor T Cell Therapy

REACH: Study to Determine the Aetiology of Chlormethine Gel Induced-skin Drug Reaction in Early Stage Mycosis Fungoides Cutaneous T Cell Lymphoma (MF-CTCL)